# NCT01804790 (NCT01804790)

> Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer

No report yet. It can be ordered.

- Indication: resectable locally advanced rectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01804790
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: UNICANCER
- Conditions: Cancer of the Rectum
- Interventions: mFolfirinox; Radiotherapy 50 Gy; Capecitabine; TME surgery; mFolfox6 or capecitabine
- Enrollment: 461
- Primary outcome: disease-free survival

## Indexed commentary on NCT01804790 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01804790